KLK3 and benign prostatic hyperplasia: CfDNA integrity, determined by the quantification of the ALU gene (i.e., ALU 247 bp ratio to ALU 115 bp), is high in PCa patients and can distinguish PCa patients from BPH patients with elevated PSA [139,140].